Literature DB >> 19886739

Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.

Lara Sanvito1, Anna Makowska, Norman Gregson, Raffaello Nemni, Richard A C Hughes.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory disease of the peripheral nervous system that is probably autoimmune in origin. Different components of the adaptive and innate immunity may be responsible for the aberrant response towards nerve antigens. To investigate this, we examined lymphocyte subsets and regulatory T cell (Treg) function in the blood of CIDP patients, healthy controls (HC) and subjects with non-immune mediated neuropathies (other neuropathies, ON). We used flow cytometry to determine the frequency of monocytes, B cells, natural killer (NK) and NK-T cells, total and activated CD4(+) and CD8(+) T cells, effector memory and central memory CD4(+) and CD8(+) T cells, and CD4(+)CD25(high)Foxp3(+) Tregs. Treg function was studied after polyclonal stimulation and antigen specific stimulation with myelin protein peptides in CIDP and HC. There was an increased frequency of monocytes (p = 0.02) and decreased frequency of NK cells (p = 0.02) in CIDP compared with HC but not ON. There were no significant differences in other populations. Treg function was impaired in CIDP compared to HC (p = 0.02), whilst T cell proliferation to myelin protein peptides before and after depletion of Tregs was not different between patients and controls. This study shows increased circulating monocytes and reduced NK cells in CIDP. Although Treg frequency was not altered, we confirm that Tregs display a defect of suppressive function. Myelin protein peptides were not the target of the altered peripheral regulation of the immune response. The mechanisms of peripheral immune tolerance in CIDP and their relevance to the pathogenesis deserve further exploration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19886739     DOI: 10.3109/08916930903140907

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  16 in total

Review 1.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

2.  Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment.

Authors:  P G Sanz; C V García Méndez; A L Cueto; V B Silva; J C Walther; R A Diez; S Martins; R J Giannaula
Journal:  Rheumatol Int       Date:  2011-09-16       Impact factor: 2.631

3.  Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients.

Authors:  J Klehmet; C Meisel; A Meisel
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Authors:  Kalliopi Pitarokoili; Min-Suk Yoon; Ilka Kröger; Anke Reinacher-Schick; Ralf Gold; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2017-08-23       Impact factor: 4.849

Review 5.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 6.  Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies.

Authors:  Jolien Wolbert; Mandy I Cheng; Gerd Meyer zu Horste; Maureen A Su
Journal:  JCI Insight       Date:  2020-02-13

Review 7.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 8.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

Review 9.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

Review 10.  Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.

Authors:  Melvin Berger; Jeffrey A Allen
Journal:  Muscle Nerve       Date:  2015-01-29       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.